Skip to main content
Signal8

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

$BIIBPress releaseMay 14, 2026, 6:59 AM ETRead the release

Biogen announced compelling topline results from the Phase 2 CELIA study of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau in early Alzheimer’s disease. The study demonstrated robust reductions in tau pathology across all studied doses, with cognitive benefit particularly evident at the lowest dose of 60 mg administered every 24 weeks. Despite not meeting the primary endpoint, Biogen plans to advance diranersen to registrational development, citing the strength of the biomarker and efficacy data.

Key figures

Drug Name
Diranersen (BIIB080)
Phase Of Trial
Phase 2

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.